{
  "docId": "019de075-d6ea-7495-b63c-e64074d45b72",
  "docSlug": "3f99bbe59467be363a98d21e99cb078a",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 58,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/10",
  "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72",
  "deckJsonHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72.json",
  "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.8,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Comparative clinical trial data charts for NXC-201, Carvykti, and Abecma",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "517a2a08-b4d3-4c0b-ab1b-b192c3562aec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.15,
        "x": 0.85,
        "y": 0.15
      },
      "kind": "list",
      "text": "1. NXC-201: Max 7-day CRS vs Others: up to 63 day CRS; 2. NXC-201: Zero Neurotoxicity vs Others: Up to 578-day neurotoxicity; 3. NXC-201: sBCMA reduced in ~30 days vs Others: ~60-155 days; 4. NXC-201: CAR-T cells exit body after sBCMA reduced vs Others: prolonged",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f094998-bd3f-40de-b5c7-2ffb7c5c264b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.96,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*NXC-201: No measurements available beyond 30 days in multiple myeloma as of the Feb 2023 data cutoff...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e94b963-08b7-44d4-b9ec-2f8baaccd69a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "N-GENIUS Technology Platform – NXC-201 rapidly eliminates relapsed/refractory multiple myeloma tumors, driving dramatically improved tolerability (1/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a8f7e25-f769-4cb0-91d7-9f77582d84ab",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "5404d079-5819-40b8-8e96-328646272f14",
      "evidence": "Comparative clinical trial data charts for NXC-201, Carvykti, and Abecma",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "a39a805f-ac38-4638-b214-3572d0e03be2",
      "evidence": "Direct visual comparison of clinical trial outcomes across three products.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 27,
      "from": 4,
      "beatId": "e890a8f4-ce5b-494a-9258-fdd0f87cc84b",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The deck presents the problem, solution, competitive analysis, and traction",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 9,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "8d02a94e-79b8-4ba4-920c-87f81d998140",
      "evidence": "The deck presents NXC-201's MoA and clinical highlights",
      "position": 0,
      "objective": "Understanding NXC-201's mechanism of action",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}